- MarketWatch•9 hours ago
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about ...
- Benzinga•2 days ago
The next generation of breast and ovarian cancer treatment is attacking the deadly disease from all angles. That is no more evident than in the glut of pharmaceutical companies racing to develop, test, ...
- GlobeNewswire•2 days ago
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration program Ongoing clinical trial expanded to enroll patients with endometrial cancer Patient-centric administration schedule ...
TSRO : Summary for TESARO, Inc. - Yahoo Finance
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||145.50 x 100|
|Ask||248.84 x 100|
|Day's Range||143.57 - 148.51|
|52 Week Range||36.68 - 192.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-18.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|